Boehringer Ingelheim teams up with IBM to explore blockchain

The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FDA selects Merck, IBM, KPMG and Walmart for blockchain pilot

17 June 2019 The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.

Big Pharma

Boehringer teams up with Gubra to develop second obesity treatment

30 May 2019 German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

Americas

IBM patent targets blockchain in open scientific research

14 November 2018 Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Boehringer Ingelheim teams up with IBM to explore blockchain

More on this story

Editor's picks

Editor's picks

More features